Incidence and risk factors of osteonecrosis of the jaw after treatment with Zoledronic acid or Denosumab in advanced cancer patients

Trial Profile

Incidence and risk factors of osteonecrosis of the jaw after treatment with Zoledronic acid or Denosumab in advanced cancer patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2016

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid (Primary)
  • Indications Breast cancer; Colon cancer; Liver cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top